Phase 1Recruiting

A Trial of Selinexor, Ruxolitinib and Methylprednisolone (KPT-IST-391)

A Phase I Trial of Selinexor, Ruxolitinib and Methylprednisolone for Patients With Relapsed/Refractory Multiple Myeloma

Sponsor
Oncotherapeutics (Industry)
Enrollment
30 planned
Conditions
Multiple Myeloma in Relapse; Multiple Myeloma, Refractory
Interventions
Selinexor; Ruxolitinib; Methylprednisolone
Ages
children, adults, older adults
Registry
NCT06225310

Full record on ClinicalTrials.gov

From the registry

Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.

Primary outcomes

  • 1. Maximum Tolerated Dose (MTD):
  • 2. Recommended phase 2 dose (RP2D)

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered